Publication | Open Access

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

UrologyPatient-reported OutcomesGenitourinary CancerMedicineCancer ManagementCabozantinib Versus SunitinibCheckmate 9ErImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyMolecular Oncology